Sandy Wong, MD, University of California, Los Angeles, CA, comments on the management of systemic immunoglobulin light chain (AL) amyloidosis, highlighting the unmet needs in this space. Dr Wong explains that whilst the current standard of care (SOC) for patients with newly diagnosed systemic amyloidosis, Dara-CyBorD (daratumumab plus cyclophosphamide, bortezomib, and dexamethasone), is very effective, it is still necessary to clarify which patients should undergo autologous hematopoietic stem cell transplantation (autoHSCT). Conversely, it is important to establish effective treatment options for transplant-ineligible patients. Dr Wong explains that several clinical trials are evaluating anti-myeloma agents in this patient population. Finally, Dr Wong shares her excitement for imaging trials in this space. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.